Presentation is loading. Please wait.

Presentation is loading. Please wait.

Division of Pharmacometrics, Reviewer

Published byGodfrey Skinner Modified over 9 years ago

Similar presentations

Presentation on theme: "Division of Pharmacometrics, Reviewer"— Presentation transcript:

1 Division of Pharmacometrics, Reviewer
Observations from the Antiviral Information Management System (AIMS) Database Jeffry Florian, Ph.D. CDER/OTS/OCP Division of Pharmacometrics, Reviewer The opinions and information in this presentation are those of the author, and do not represent the views and/or policies of the U.S. Food and Drug Administration.

2 Overview of the Antiviral Information Management System (AIMS)
Outline Overview of the Antiviral Information Management System (AIMS) Observations and analyses from AIMS EOP2 NDA Trial design Future project considerations with the database

3 Project started in 2008 – Critical Path Initiative
A system to archive data and assist analysis for new anti-HCV agents is needed to inform dose selection. With more than forty new anti-HCV drugs in the pipeline, we must keep pace with development. BOTTLENECK: Lack of available database & data standards 40+ HCV drugs in development Modeling and simulation can help inform dosing and trial design issues for efficient development. Systematic archival of data and analysis will help leverage prior knowledge in this emerging therapeutic area. Project started in 2008 – Critical Path Initiative Dr. Gobburu and Dr. Jadhav

4 Modeling codes and analyses
AIMS database relies on : (1) Database standards, (2) Data requests (3) Internal analysis codes, and (4) Shared experience AIMS Database Standards Analysis Data Mean viral load : 1a 1b log10 HCV RNA time (weeks) Modeling codes and analyses Fraction achieving SVR Time (weeks) 1.0 0.5

5 Relationship Diagram:
Implementation of the relational database structure, data templates and controlled terms requires forward thinking and planning. AIMS Database Relationship Diagram: Relational structure supports efficient queries Sponsors will receive a data template and a list of controlled terms to guide data submission. Templates: definitions and examples for all data fields. Controlled Terms: specific listing of acceptable inputs for each data field to ensure identical formatting for all sponsors. CM CM EX EX concomitant meds exposure PC PC pharmacokinetics DRUG DRUG STUDY STUDY DM DM MB MB demographics virology VS VS Analysis data specific for HCV vital signs Raw data in abbreviated CDISC format EP EP LB LB endpoints lab measures

6 The available information depends on the active and willing collaboration of sponsors developing HCV drugs Original information request was issued in July 2010 to all companies with an active HCV IND New data request issued whenever a sponsor submits a new IND Voluntary data submission of completed trials according to the provided data standard. Request data at the time of End-of-Phase 2, End-of-Phase 2A, or other key early development meetings

7 Every day is like drinking from a fire hose

8 Recent Phase III trials were submitted according to AIMS standard.
The AIMS database contains demographic, PK, virologic, and treatment data from previous, recent, and ongoing trials. 9 drug development programs 29 studies 10K+ subjects Legacy data were converted using internal resources to include in the database. Recent Phase III trials were submitted according to AIMS standard. Many EOP2 meetings have accompanying AIMS datasets Multiple treatment regimens (PR, PR+DAA) and durations were included in the dataset.

9 Archive data from sponsors without additional formatting.
The AIMS database assists reviewers in analyses across all HCV submissions In addition ... Use archived HCV data to generate research hypotheses across multiple studies and drugs. Archive data from sponsors without additional formatting. Generate analysis datasets, plots and reports using automated scripts. Archive analysis results (data, models, plots, reports). Access historic data to inform decisions about new submissions.

10 Outline Overview of the Antiviral Information Management System (AIMS)
Observations and analyses from AIMS EOP2 NDA Trial design Future project considerations with the database

11 AIMS database has aided reviewers in dose selection and treatment duration during early drug development. DRUG REVIEW QUESTION RESULT Drug X (EOP2) What dose/duration to use in Phase III? Explore different regimens in two proposed later trials Drug Y (EOP2) Does the loading dose improve efficacy? Later trials removed loading dose Drug Z (EOP2) Is the proposed dosing regimen reasonable? Is the proposed duration for reasonable? Longer treatment durations were explored in later phase trials. Involved in 16+ EOP2/EOP2A/Type C meetings

12 AIMS datasets have been provided for ~50% of early phase meetings
Sponsors are submitting materials to support and justify doses, treatment durations, and patient population A majority of EOP2 submission packages are accompanied by modeling and simulation results Supportive analyses for regimen(s) selected for registrational trials Viral kinetic modeling including resistance and viral subtypes Predictions of SVR using studied and/or exploratory regimens Exposure-response safety analyses for key signals identified in Phase II AIMS datasets have been provided for ~50% of early phase meetings Data conversion and standardization is time consuming not commonly performed until later in drug development Sponsors provide datasets for modeling and simulation whenever available

13 General observations over multiple EOP2 submissions
As regimens are becoming better (↑SVR, ↓treatment duration), the need for earlier assessments increases Intrinsic patient factors remain important for treatment outcome (e.g., IL28B, cirrhosis, baseline HCV RNA) Genotype subtype is becoming more important (ref: Dr. Harrington) P/R-regimens: time to HCV RNA not detected remains predictive of response The impact of shortening treatment duration may require even earlier metrics (eRVR or even ‘Week 1’VR) IFN-free regimens: antiviral activity ≠ SVR Predictive factors based on viral kinetics remain to be identified Much easier to identify when something is not optimal

14 Outline Overview of the Antiviral Information Management System (AIMS)
Observations and analyses from AIMS EOP2 NDA Trial design Future project considerations with the database

15 Two programs, same story
Two new HCV therapies characterized by drastically different drug development programs REGISTRATIONAL TRIAL DESIGNS BOCEPREVIR TELAPREVIR Lead-in Phase YES NO Response Guided Therapy All trials Only treatment-naïve patients Treatment-experienced trial Excludes null responders Include relapsers, partial responders, and null responders Two programs, same story

16 “Bridging” Observations Through Interferon Responsiveness
Similar response with first or second round of P/R treatment Data for previously treated subjects are “bridged” with data from untreated subjects Previously treated subjects are represented within untreated subjects P/R treatment for HCV is unlike HIV treatment which frequently leads to resistance and does not yield similar virologic response on subsequent courses of treatment

17 Similar Virologic Response at Week 4 with First or Second PR treatment (pooled analysis)
1416 468 597 219 507 112 548 Liu et al. CID 2012

18 Standardized datasets facilitated similar analyses and led to novel dosing recommendations.
EXAMPLE REVIEW QUESTIONS RESULT Telaprevir Pivotal trials did not evaluate shorter treatment durations in relapse patients Additional study deemed unnecessary. Shorter treatment duration included in label for prior relapsers Boceprevir Prior null responders not included in Phase III Different regimens for treatment-naïve (TN) and treatment-experienced (TE) trials Evidence of effectiveness for prior null responders Dosing recommendations for TN late responders A successful trial in TE subjects can serve as evidence of effectiveness to support dosing and approval in TN subjects.

19 Outline Overview of the Antiviral Information Management System (AIMS)
Observations and analyses from AIMS EOP2 NDA Trial design Future project considerations with the database

20 Endpoint is assessed 24 weeks after the end of treatment
SVR24 was the surrogate endpoint used in original Peg-IFN/RBV and recent DAA+Peg-IFN/RBV trials TREATMENT Follow-up Wk 24 8 24 16 40 32 48 60 72 WEEK 60-70% 30-40% Endpoint is assessed 24 weeks after the end of treatment Follow-up duration may be as long as treatment SVR12 (HCV not detected at 12 weeks post treatment) is evidence of effectiveness in Phase II Can a similar assessment be used in Phase III?

21 Concordance was observed between SVR12 and SVR24 for all Peg-IFN/RBV and DAA+Peg-IFN/RBV treatments
SVR 24 Assessment ‘Y’ ‘N’ SVR12 Assessment 5428 93 56 4617 ~2% of patients with SVR12 relapse by SVR24 assessment (false positive) PPV: 98% NPV: 99% Sensitivity: 99% Specificity: 98.0% SVR 24 Assessment ‘Y’ ‘N’ SVR4 Assessment 4239 412 53 3002 Less agreement between SVR4 and SVR24 SVR4 may be useful for guiding dose selection PPV: 91.1% NPV: 98.2% Sensitivity: 98.7% 21 Specificity: 87.7% 21

22 Sensitivity analyses support that SVR12 and SVR24 are concordant for Peg-IFN/RBV containing regimens
 SVR 24 Assessment PPI SVR 12 ‘Y’ (P/R Arms - all) 98.1% SVR 12 ‘Y’ (DAA Arms) 98.8% RGT (DAA Arms) 98.9% No RGT (DAA Arms) Overall 2% No matter how the analysis was performed 1-3% of patients relapse between SVR12 and SVR24

23 The analysis of SVR12/SVR24 for genotype 1 subjects motivated similar analyses for other populations and different regimens Subsequent application of the same analysis demonstrated concordance for Pediatrics Genotype 2/3 G2/3 IFN-free regimens: Additional data is required Provide all available SVR12 and SVR24 data from drug development program and discuss (all regimens)

24 Outline Overview of the Antiviral Information Management System (AIMS)
Observations and analyses from AIMS EOP2 NDA Trial design Future project considerations with the database

25 Compatible with AIMS datasets submitted by sponsors
eDISH (Evaluation of Drug-Induced Serious Hepatotoxicity) – FDA reviewer tool eDISH is a tool developed to assist reviewers in analyzing/explaining DILI in an IND/NDA Compatible with AIMS datasets submitted by sponsors

26 eDISH includes time plots of key laboratory values
eDISH (Evaluation of Drug-Induced Serious Hepatotoxicity) – FDA reviewer tool (cont.) eDISH includes time plots of key laboratory values Data is linked to individual patient narratives May assist in the safety analyses for IFN-free regimens 26

27 Conclusions Sponsors are submitting datasets for AIMS
These datasets are assisting in the review of submissions at EOP2 meetings Information from these submissions has provided insight regarding subsequent HCV trial design Future projects will continue to be evaluated as additional data becomes available

28 Acknowledgements Division of Antiviral Products
Critical Path Initiative and ORISE Lauren Neal Jianmeng Chen OCP (Division of Clinical Pharmacology IV) John Lazor Kellie Reynolds Sarah Robertson Vikram Arya Stanley Au Ruben Ayala Shirley Seo Jenny Zheng OCP (Division of Pharmacometrics) Joga Gobburu Pravin Jadhav Yaning Wang Ying Chen Division of Antiviral Products Debra Birnkrant Jeff Murray Many supportive medical reviewers and project managers DAVP Clinical Virology Team Patrick Harrington Jules O’Rear Lisa Naeger NCTR Steve Hodge Edward Bearden OTS Chuck Cooper Office of Biometrics Ted Guo Many subjects, investigators, and sponsors who have provided data

29 Questions

Download ppt "Division of Pharmacometrics, Reviewer"

Similar presentations

Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.

Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.
The Importance of CDASH

The Importance of CDASH
1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.

1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
1 FDA Perspective on Direct Acting Antiviral Trials Wendy Carter, D.O. Medical Officer Division of Antiviral Products US Food and Drug Administration The.

1 FDA Perspective on Direct Acting Antiviral Trials Wendy Carter, D.O. Medical Officer Division of Antiviral Products US Food and Drug Administration The.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
REGULATORY ISSUES IN HIV CURE RESEARCH HIV Cure Research Training Curriculum Regulatory Issues Module by: Damon Deming, Ph.D. FDA Division of Antiviral.

REGULATORY ISSUES IN HIV CURE RESEARCH HIV Cure Research Training Curriculum Regulatory Issues Module by: Damon Deming, Ph.D. FDA Division of Antiviral.
IL28B in the Era of DAA Therapy: Ten Years Too Late? Donald M. Jensen, MD Professor of Medicine Director, Center for Liver Disease University of Chicago.

IL28B in the Era of DAA Therapy: Ten Years Too Late? Donald M. Jensen, MD Professor of Medicine Director, Center for Liver Disease University of Chicago.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:

ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.
1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.

1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.
JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
1 FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.

1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.
Gastroenterology Volume 142, Issue 4, April 2012, Pages 790–795 Tom W. Chu.

Gastroenterology Volume 142, Issue 4, April 2012, Pages 790–795 Tom W. Chu.
Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office.

Department of Health and Human Services Food and Drug Administration DMETS Evaluation of Proprietary Names Jerry Phillips, RPh Associate Director Office.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:

ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Similar presentations

Ads by Google